Half-year report · Q2
7459.TEDINET S100UQW8
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.82T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.78T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥27.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥35.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥29.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥39.8bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥32.8bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥21.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥27.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥22.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.88T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.80T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.82T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.12T | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.06T | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥757.7bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥736.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥714.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥251.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥230.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥249.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥207.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥41.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥31.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥103.94 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.48 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥161m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥600.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥600.2bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥201m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.83T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥27.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥37m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥56.8bn |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥583.4bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥583.3bn |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥146m |
| jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.14T |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.78T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥20.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Rents sga | CurrentYTDDuration | 2493000000 | JPY |
| Depreciation sga | Prior1YTDDuration | 6604000000 | JPY |
| Depreciation sga | CurrentYTDDuration | 6732000000 | JPY |
| Other sga | Prior1YTDDuration | 30142000000 | JPY |
| Other sga | CurrentYTDDuration | 25251000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 100744000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 99278000000 | JPY |
| Operating income | Prior1YTDDuration | 20631000000 | JPY |
| Operating income | CurrentYTDDuration | 27162000000 | JPY |
| Interest income noi | Prior1YTDDuration | 13000000 | JPY |
| Interest income noi | CurrentYTDDuration | 12000000 | JPY |
| Dividends income noi | Prior1YTDDuration | 1431000000 | JPY |
| Dividends income noi | CurrentYTDDuration | 1565000000 | JPY |
| Research fee income noi | Prior1YTDDuration | 4217000000 | JPY |
| Research fee income noi | CurrentYTDDuration | 4260000000 | JPY |
| Real estate rent noi | Prior1YTDDuration | 1079000000 | JPY |
| Real estate rent noi | CurrentYTDDuration | 1223000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YTDDuration | 1900000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYTDDuration | 606000000 | JPY |
| Other noi | Prior1YTDDuration | 954000000 | JPY |
| Other noi | CurrentYTDDuration | 1241000000 | JPY |
| Non operating income | Prior1YTDDuration | 9596000000 | JPY |
| Non operating income | CurrentYTDDuration | 8909000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 4000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 3000000 | JPY |
| Rent expenses on real estates noe | Prior1YTDDuration | 567000000 | JPY |
| Rent expenses on real estates noe | CurrentYTDDuration | 826000000 | JPY |
| Loss on investments in partnership noe | Prior1YTDDuration | 248000000 | JPY |
| Loss on investments in partnership noe | CurrentYTDDuration | 24000000 | JPY |
| Other noe | Prior1YTDDuration | 107000000 | JPY |
| Other noe | CurrentYTDDuration | 137000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 928000000 | JPY |
| Non operating expenses | CurrentYTDDuration | 991000000 | JPY |
| Ordinary income | Prior1YTDDuration | 29299000000 | JPY |
| Ordinary income | CurrentYTDDuration | 35080000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 0 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | 1000000 | JPY |
| Gain on step acquisitions ei | Prior1YTDDuration | 1253000000 | JPY |
| Gain on step acquisitions ei | CurrentYTDDuration | 32000000 | JPY |
| Gain on sales of investment securities ei | Prior1YTDDuration | 447000000 | JPY |
| Gain on sales of investment securities ei | CurrentYTDDuration | 4912000000 | JPY |
| Compensation income ei | Prior1YTDDuration | 1944000000 | JPY |
| Compensation income ei | CurrentYTDDuration | － | JPY |
| Other ei | Prior1YTDDuration | － | JPY |
| Other ei | CurrentYTDDuration | 37000000 | JPY |
| Extraordinary income | Prior1YTDDuration | 3645000000 | JPY |
| Extraordinary income | CurrentYTDDuration | 4983000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1YTDDuration | 12000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | CurrentYTDDuration | 28000000 | JPY |
| Impairment loss el | Prior1YTDDuration | 67000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |